Immunotherapy最新文献_第2页

Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report. 埃夫加替莫德治疗派姆单抗诱导的心肌炎、肌炎和重症肌无力重叠综合征（IM3OS） 1例

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1080/1750743X.2025.2517522

Stephanie S Cobelas-Cartagena, Emilio Amigo-Otero, Victoria García-Samblas, Jesus Flores-Raposo, Silvia Rodrigo-Herrero, Juan Bayo-Calero

引用次数: 0

Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma. 评价莫加单抗治疗原发性皮肤t细胞淋巴瘤的疗效。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-24 DOI: 10.1080/1750743X.2025.2520153

M Oymanns, K Elsayad, L Wilms, F Dimmers, M Daum-Marzian, R Abu-Dawud, M Motiei, C Assaf

{"title":"Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.","authors":"M Oymanns, K Elsayad, L Wilms, F Dimmers, M Daum-Marzian, R Abu-Dawud, M Motiei, C Assaf","doi":"10.1080/1750743X.2025.2520153","DOIUrl":"10.1080/1750743X.2025.2520153","url":null,"abstract":"Mogamulizumab is a humanized monoclonal antibody targeting CCR4, a chemokine receptor expressed on T-cells, including malignant cells found in cutaneous T-cell lymphoma (CTCL). CTCL represents a heterogeneous group of skin lymphomas, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common subtypes. Despite various treatment options, advanced stages of CTCL often present a challenge, with limited long-term therapeutic success. Mogamulizumab has demonstrated promise in treating relapsed or refractory CTCL.Clinical trials have shown that mogamulizumab effectively targets CCR4-positive malignant T-cells, leading to tumor regression and improved survival in patients with advanced CTCL. Its ability to deplete malignant T-cells, alongside its immunomodulatory effects, contributes to its potential as a critical therapeutic agent in this setting. In both, Phase III and real-world evidence studies, mogamulizumab has demonstrated an impressive overall response rate, progression-free survival in patients with MF and SS, along with a manageable safety profile.As a promising treatment option for patients with relapsed or refractory CTCL, mogamulizumab is currently being investigated in several ongoing clinical trials, exploring its efficacy both, as a monotherapy and in combination with other treatments. Continued research and long-term follow-up are essential to optimize its application across diverse clinical settings in CTCL.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"551-559"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy. 接受免疫治疗的实体瘤患者胃肠道（GI）免疫相关不良事件的缓解策略

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-06 DOI: 10.1080/1750743X.2025.2516995

Angioletta Lasagna

引用次数: 0

Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary. 利来替尼研究中患者对头发再生的满意度：一个简单的语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-26 DOI: 10.1080/1750743X.2025.2513849

Rodney Sinclair, Ernest H Law, Xingqi Zhang, Fan Zhang, Lynne Napatalung, Samuel H Zwillich, Brett King, Natasha Mesinkovska

引用次数: 0

Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience. 纳武单抗在转移性头颈部鳞状细胞癌患者中的时间毒性：单一机构的经验。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1080/1750743X.2025.2518913

Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo

{"title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.","authors":"Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo","doi":"10.1080/1750743X.2025.2518913","DOIUrl":"10.1080/1750743X.2025.2518913","url":null,"abstract":"Background: Treatment of platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (r/mHNSCC) involves immune-checkpoint inhibitors. Time toxicity (TT) is an emerging metric with implications for patient quality of life and decision-making. We sought to evaluate TT associated with nivolumab in these patients.Methods: This is a retrospective single-institution review of patients with platinum-refractory r/mHNSCC seen at an academic cancer center between 1 January 2018 to 31 December 2022 in Ontario, Canada. Primary outcome is TT, defined as any number of days spent undergoing cancer-related activities.Results: Of 56 patients evaluated, median age was 63 years (33-85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1-109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders. TT accounted for only 4-6% for patients who survived more than a year.Conclusions: Our study provides an important and underexplored patient-centered metric in TT, especially in the context of incurable HNSCC with abysmal survival outcome. Our findings suggest that TT varies significantly between responders and non-responders. Duration of TT should be discussed with patients in shared decision-making when discussing palliative nivolumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"577-583"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report. 非小细胞肺癌合并HBV和EBV感染患者的免疫检查点抑制剂相关性结肠炎1例报告

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-01 DOI: 10.1080/1750743X.2025.2527023

Chao Han, Sujuan Xi, Te Shi, Haiyan Yue

引用次数: 0

NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy. NKT细胞——疾病治疗的通才，开启免疫治疗的新钥匙。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-29 DOI: 10.1080/1750743X.2025.2525739

Guanhua Lyu, Xu Wang, Xixi Li, Peiwen Li, Yurou Chen, Xinyao Zhang, Yuping Ren, Xunuo Sun, Xinmei Wang, Xiangyu Wang, Junyu Liu

{"title":"NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.","authors":"Guanhua Lyu, Xu Wang, Xixi Li, Peiwen Li, Yurou Chen, Xinyao Zhang, Yuping Ren, Xunuo Sun, Xinmei Wang, Xiangyu Wang, Junyu Liu","doi":"10.1080/1750743X.2025.2525739","DOIUrl":"10.1080/1750743X.2025.2525739","url":null,"abstract":"NKT cells (natural killer T cells) are a subpopulation of specialized T cells that recognize lipid antigens presented by CD1d molecules, which can be classified into type I NKT cells, type II NKT cells and NKT-like cells. NKT cells play a key role in linking innate and adaptive immunity. In recent years, NKT cells have been found to be involved in the development of various systemic diseases, including tumors, respiratory system diseases, autoimmune diseases, reproductive system diseases, gastrointestinal system diseases and liver diseases. Thus, immunotherapy targeting NKT cells has brought novel strategies for the treatment of cancers and other diseases. Currently, NKT cell-based immunotherapy includes NKT cell agonist, CAR-NKT and NKT gene editing. Among them, α-galactosylceramide (α-GalCer), a NKT cell agonist, has demonstrated promising applications in enhancing vaccine immunogenicity and anti-tumor immunity. In conclusion, this review systematically summarizes the development, differentiation, classification, and function of NKT cells, as well as their relationships with systemic diseases. Additionally, this review also emphasizes the prospects for the clinical application of NKT cell-based immunotherapy. Future research should focus on the development of novel NKT cell-targeted therapeutic strategies and vaccine adjuvants to advance personalized medicine and precision immunotherapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"667-683"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study. nivolumab治疗转移性肾细胞癌的尿酸水平：土耳其肿瘤组肾癌联盟（TKCC）的一项研究

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-03 DOI: 10.1080/1750743X.2025.2527019

Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün

{"title":"Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.","authors":"Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün","doi":"10.1080/1750743X.2025.2527019","DOIUrl":"10.1080/1750743X.2025.2527019","url":null,"abstract":"Aims: To investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Materials and methods: This retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across Türkiye.Results and conclusions: A total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months, p = 0.014) and OS (52.01 vs. 25.36, p = 0.032) in the uric acid-high (UAH) group than in the uric acid-low (UAL) group. In multivariable analyses, low uric acid level emerged as an independent risk factor for OS (hazard ratio (HR): 1.82, 95% confidence interval (CI): 1.09-3.05; p = 0.022), whereas no significant association was observed with TTF (HR: 1.24, 95% CI: 0.72-2.13; p = 0.431). While uric acid levels were a significant independent prognostic factor for OS, no association was found with TTF. Our findings underscore the prognostic importance of uric acid in mRCC, suggesting its potential role as a biomarker for risk stratification.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"649-655"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IgE-mediated anaphylaxis induced by pembrolizumab. 派姆单抗诱导ige介导的过敏反应。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-08 DOI: 10.1080/1750743X.2025.2527589

Romane Legroux, Jeanne-Marie Perotin, Gabrielle Wintrebert, Julien Ancel

{"title":"IgE-mediated anaphylaxis induced by pembrolizumab.","authors":"Romane Legroux, Jeanne-Marie Perotin, Gabrielle Wintrebert, Julien Ancel","doi":"10.1080/1750743X.2025.2527589","DOIUrl":"10.1080/1750743X.2025.2527589","url":null,"abstract":"The increasing use of biologics in cancer treatment is associated with an increase in drug-related hypersensitivity reactions (HSR) of varying severity. Pembrolizumab is a humanized monoclonal antibody specifically targeting the programmed cell death protein 1 (PD-1) receptor, largely used in lung cancer and other malignancies. Pembrolizumab-related HSR has rarely been described, with very few reported positive allergy tests.We describe the case of a 77-year-old man treated for metastatic lung adenocarcinoma, who presented a severe anaphylactic reaction during the 8th pembrolizumab administration. Allergy tests confirmed the type I IgE-mediated hypersensitivity mechanism.Based on the four published cases, immediate HSR induced by pembrolizumab can occur after several treatment courses with potentially severe anaphylactic reactions. Mild symptoms during the preceding courses might occur and should be monitored. Skin tests are reliable, safe, and useful to guide management. When immediate HSR induced by pembrolizumab is confirmed, rapid drug desensitization may be considered. Further studies are needed to identify risk factors for immediate HSR induced by pembrolizumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"625-629"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack. 溶瘤免疫病毒治疗：在抗病毒药物的大海捞针中寻找肿瘤抗原。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-06 DOI: 10.1080/1750743X.2025.2513853

Benjamin L Kendall, Richard G Vile

{"title":"Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.","authors":"Benjamin L Kendall, Richard G Vile","doi":"10.1080/1750743X.2025.2513853","DOIUrl":"10.1080/1750743X.2025.2513853","url":null,"abstract":"Immunovirotherapy integrates the oncolytic capabilities of viruses with the modulation of the host immune system to establish robust tumor-specific immune responses. Oncolytic viruses (OVs) are natural or engineered viruses that specifically replicate in and lyse tumor cells, triggering inflammation which recruits immune effector cells to the site of infection. These conditions theoretically synergize with immune checkpoint blockade (ICB), which aids in establishing and maintaining tumor-infiltrating CD8 T cells. However, clinical data directly confirming synergy between OV and ICB therapy is limited despite ICB becoming the standard of care for several cancer types. It has been shown that viral immunodominance may limit antitumor T-cell priming and cause the attrition of tumor-specific T cells, limiting long-term therapeutic efficacy. To overcome these barriers, precise incorporation of virally expressed or exogenously administered tumor-associated antigens (TAAs) can synchronize the expansion of both antiviral and antitumor T cells, creating optimal conditions for ICB treatment. This tripartite approach leverages our understanding of antiviral immunity to efficiently expand subdominant antitumor T cells in vivo. In this review, we dissect the fundamental paradigm of immunovirotherapy regarding antiviral inflammation and TAAs, followed by relevant combinatorial strategies employed in preclinical and clinical settings for the treatment of solid tumors.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"585-594"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0